Sandoz Expands Diabetes Treatment Options in Brazil with Semaglutide Launch

Sandoz Group AG has introduced Owozy™, a new semaglutide injection, in Brazil. As one of the world's leading and fast-growing GLP-1 markets, Brazil represents a significant milestone for Sandoz. With over 16.5 million Brazilians living with diabetes, the launch aims to address a critical public health challenge.

Owozy, developed by Adalvo and approved by ANVISA, will be distributed in Brazil by Biolab & Co. It is offered in a pre-filled pen designed for ease of use by patients and healthcare professionals. This launch follows recent approvals in Canada and regulatory advancements in the US, strengthening Sandoz's position in the generic GLP-1 market.

The initiative supports Sandoz's broader strategy to enhance global access to affordable medicines through its extensive portfolio and innovative pipeline. Despite the launch's significance, no immediate financial impact is anticipated for Sandoz this year.